Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Innate Pharma S.A. IPHA
$3.03
-$0.01 (-0.33%)
На 18:01, 12 мая 2023
+230.03%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
240599335.00000000
-
week52high
3.97
-
week52low
1.90
-
Revenue
49639000
-
P/E TTM
-2
-
Beta
0.32213700
-
EPS
-0.79000000
-
Last Dividend
0.00000000
-
Next Earnings Date
23 мар 2023 г. в 04:00
Описание компании
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 02 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 11 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 17 сент 2021 г. |
| SVB Leerink | Outperform | Market Perform | 03 сент 2021 г. |
| SVB Leerink | Outperform | Market Perform | 02 сент 2021 г. |
| Citigroup | Buy | Buy | 16 сент 2022 г. |
| SVB Leerink | Outperform | Outperform | 15 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Innate Pharma to Participate in Upcoming Investor Conferences
Business Wire
07 февр 2023 г. в 01:00
Penny Stocks To Buy Now? 6 To Watch With Big News Today
PennyStocks
19 дек 2022 г. в 09:33
Hot penny stocks to watch with big news this week. The post Penny Stocks To Buy Now?
Innate Pharma S.A. (IPHA) Q3 2022 Earnings Call Transcript
Seeking Alpha
14 ноя 2022 г. в 14:40
Innate Pharma S.A. (NASDAQ:IPHA ) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Henry Wheeler – Head-Investor Relations Mondher Mahjoubi – Chief Executive Officer Joyson Karakunnel – Executive Vice President and Chief Medical Officer Yannis Morel – Executive Vice President-Business Development and Product Portfolio Strategy Conference Call Participants Yigal Nochomovitz – Citigroup Daina Graybosch – SVB Securities Swayampakula Ramakanth – HCW Operator Hello, and thank you for standing by.
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update
Business Wire
07 ноя 2022 г. в 01:00
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for third quarter 2022 business update
Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022
Business Wire
04 ноя 2022 г. в 02:00
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the following presentations will be presented at the 64th ASH (American Society Hematology) Annual Meeting taking place from December 10-13, 2022, in New Orleans, Louisiana.